JP2004506695A5 - - Google Patents

Download PDF

Info

Publication number
JP2004506695A5
JP2004506695A5 JP2002520852A JP2002520852A JP2004506695A5 JP 2004506695 A5 JP2004506695 A5 JP 2004506695A5 JP 2002520852 A JP2002520852 A JP 2002520852A JP 2002520852 A JP2002520852 A JP 2002520852A JP 2004506695 A5 JP2004506695 A5 JP 2004506695A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
chimeric monoclonal
subject
antibody
cariogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002520852A
Other languages
Japanese (ja)
Other versions
JP2004506695A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/023277 external-priority patent/WO2002015931A1/en
Publication of JP2004506695A publication Critical patent/JP2004506695A/en
Publication of JP2004506695A5 publication Critical patent/JP2004506695A5/ja
Pending legal-status Critical Current

Links

Claims (32)

治療の必要な被験体にキメラモノクローナル抗体を投与することを含む、う蝕原性生物に対する体液性免疫応答を誘導する方法であって、キメラモノクローナル抗体は、う蝕原性生物に特異的に結合し、かつ被験体からのう蝕原性生物により示される抗原に対する体液性免疫応答を誘発し、う蝕原性生物に結合するキメラモノクローナル抗体の部分は、そのような治療の必要な被験体の種とは異なる種から得られる、上記方法。A method of inducing a humoral immune response against a cariogenic organism comprising administering the chimeric monoclonal antibody to a subject in need of treatment, wherein the chimeric monoclonal antibody specifically binds to the cariogenic organism And the portion of the chimeric monoclonal antibody that elicits a humoral immune response against the antigen exhibited by the cariogenic organism from the subject and binds to the cariogenic organism is of the subject in need of such treatment. The above method, obtained from a species different from the species. う蝕原性生物がエス・ミュータンス（S. mutans）である、請求項１の方法。The method of claim 1, wherein the cariogenic organism is S. mutans. キメラモノクローナル抗体が、エス・ミュータンス（S. mutans）に特異的に結合するモノクローナル抗体の相補性決定領域を含む、請求項１の方法。2. The method of claim 1, wherein the chimeric monoclonal antibody comprises a complementarity determining region of a monoclonal antibody that specifically binds to S. mutans. キメラモノクローナル抗体が、アメリカンタイプカルチャーコレクションに、ATCC No. 1) HB12559（SWLA1と呼ぶ）、2) HB12560（SWLA2と呼ぶ）、または3) HB12258（SWLA3と呼ぶ）として寄託されたハイブリドーマにより産生されるモノクローナル抗体の相補性決定領域を含む、請求項１の方法。Chimeric monoclonal antibodies are produced by hybridomas deposited with the American Type Culture Collection as ATCC No. 1) HB12559 (referred to as SWLA1), 2) HB12560 (referred to as SWLA2), or 3) HB12258 (referred to as SWLA3) 2. The method of claim 1 comprising the complementarity determining region of a monoclonal antibody. キメラモノクローナル抗体が、IgG抗体またはIgM抗体の定常領域を含む、請求項１の方法。2. The method of claim 1, wherein the chimeric monoclonal antibody comprises an IgG antibody or IgM antibody constant region. 治療の必要な被験体がヒトであり、キメラモノクローナル抗体は、ヒトIgG抗体またはIgM抗体の定常領域を含む、請求項１の方法。2. The method of claim 1, wherein the subject in need of treatment is a human and the chimeric monoclonal antibody comprises a constant region of a human IgG antibody or IgM antibody. キメラモノクローナル抗体が、組換えキメラモノクローナル抗体である、請求項１の方法。The method of claim 1, wherein the chimeric monoclonal antibody is a recombinant chimeric monoclonal antibody. キメラモノクローナル抗体がトランスジェニック植物から産生される、請求項１の方法。2. The method of claim 1, wherein the chimeric monoclonal antibody is produced from a transgenic plant. 治療の必要な被験体が哺乳動物である、請求項１の方法。2. The method of claim 1, wherein the subject in need of treatment is a mammal. 治療の必要な被験体が、ヒト、イヌ、またはネコである、請求項１の方法。2. The method of claim 1, wherein the subject in need of treatment is a human, dog or cat. キメラモノクローナル抗体が経口投与される、請求項１の方法。2. The method of claim 1, wherein the chimeric monoclonal antibody is administered orally. 治療の必要な被験体にキメラモノクローナル抗体を投与することを含む、う蝕を治療または予防する方法であって、キメラ抗体は、う蝕に関連するう蝕原性生物に特異的に結合し、かつ被験体からのう蝕原性生物により示される抗原に対する体液性免疫応答を誘発し、う蝕原性生物に結合するキメラモノクローナル抗体の部分は、治療の必要な被験体の種とは異なる種から得られる、上記方法。A method of treating or preventing caries comprising administering a chimeric monoclonal antibody to a subject in need of treatment, wherein the chimeric antibody specifically binds to a cariogenic organism associated with caries, And the portion of the chimeric monoclonal antibody that elicits a humoral immune response against the antigen exhibited by the cariogenic organism from the subject and binds to the cariogenic organism is a species different from that of the subject in need of treatment. Obtained from the above process. う蝕原性生物がエス・ミュータンス（S. mutans）である、請求項１２の方法。13. The method of claim 12, wherein the cariogenic organism is S. mutans. キメラモノクローナル抗体が、エス・ミュータンス（S. mutans）に特異的に結合するモノクローナル抗体の相補性決定領域を含む、請求項１２の方法。13. The method of claim 12, wherein the chimeric monoclonal antibody comprises a complementarity determining region of a monoclonal antibody that specifically binds to S. mutans. キメラモノクローナル抗体が、アメリカンタイプカルチャーコレクションに、ATCC No. 1) HB12559（SWLA1と呼ぶ）、2) HB12560（SWLA2と呼ぶ）、または3) HB12258（SWLA3と呼ぶ）として寄託されたハイブリドーマにより産生されるモノクローナル抗体の相補性決定領域を含む、請求項１２の方法。Chimeric monoclonal antibodies are produced by hybridomas deposited with the American Type Culture Collection as ATCC No. 1) HB12559 (referred to as SWLA1), 2) HB12560 (referred to as SWLA2), or 3) HB12258 (referred to as SWLA3) 13. The method of claim 12, comprising a monoclonal antibody complementarity determining region. キメラモノクローナル抗体が、IgG抗体またはIgM抗体の定常領域を含む、請求項１２の方法。13. The method of claim 12, wherein the chimeric monoclonal antibody comprises an IgG antibody or IgM antibody constant region. そのような治療の必要な被験体がヒトであり、キメラモノクローナル抗体は、ヒトIgG抗体またはIgM抗体の定常領域を含む、請求項１２の方法。13. The method of claim 12, wherein the subject in need of such treatment is a human and the chimeric monoclonal antibody comprises a constant region of a human IgG antibody or IgM antibody. キメラモノクローナル抗体が、組換えキメラモノクローナル抗体である、請求項１２の方法。13. The method of claim 12, wherein the chimeric monoclonal antibody is a recombinant chimeric monoclonal antibody. キメラモノクローナル抗体がトランスジェニック植物から産生される、請求項１２の方法。13. The method of claim 12, wherein the chimeric monoclonal antibody is produced from a transgenic plant. 治療の必要な被験体が哺乳動物である、請求項１２の方法。13. The method of claim 12, wherein the subject in need of treatment is a mammal. 治療の必要な被験体が、ヒト、イヌ、またはネコである、請求項１２の方法。13. The method of claim 12, wherein the subject in need of treatment is a human, dog or cat. キメラモノクローナル抗体が経口投与される、請求項１２の方法。13. The method of claim 12, wherein the chimeric monoclonal antibody is administered orally. う蝕原性生物に特異的に結合し、かつう蝕原性生物の宿主となる被験体中のう蝕原性生物により示される抗原に対する体液性免疫応答を誘発するキメラモノクローナル抗体であって、う蝕原性生物に結合するモノクローナル抗体の部分は、う蝕原性生物の宿主となる被験体の種とは異なる種から得られる、上記抗体。A chimeric monoclonal antibody that specifically binds to a cariogenic organism and elicits a humoral immune response against an antigen exhibited by the cariogenic organism in a subject hosting the cariogenic organism, comprising: The above-described antibody, wherein the portion of the monoclonal antibody that binds to the cariogenic organism is obtained from a species different from the species of the subject that is the host of the cariogenic organism. う蝕原性生物がエス・ミュータンス（S. mutans）である、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, wherein the cariogenic organism is S. mutans. う蝕原性生物に結合するモノクローナル抗体の部分が、エス・ミュータンス（S. mutans）に特異的に結合するモノクローナル抗体の相補性決定領域を含む、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, wherein the portion of the monoclonal antibody that binds to a cariogenic organism comprises a complementarity determining region of a monoclonal antibody that specifically binds to S. mutans. う蝕原性生物に結合するモノクローナル抗体の部分は、アメリカンタイプカルチャーコレクションに、ATCC No. 1) HB12559（SWLA1と呼ぶ）、2) HB12560（SWLA2と呼ぶ）、または3) HB12258（SWLA3と呼ぶ）として寄託されたハイブリドーマにより産生されるモノクローナル抗体の相補性決定領域を含む、請求項２３のキメラモノクローナル抗体。The part of the monoclonal antibody that binds to cariogenic organisms is listed in the American Type Culture Collection as ATCC No. 1) HB12559 (referred to as SWLA1), 2) HB12560 (referred to as SWLA2), or 3) HB12258 (referred to as SWLA3) 24. The chimeric monoclonal antibody of claim 23, comprising a complementarity determining region of a monoclonal antibody produced by a hybridoma deposited as: IgG抗体またはIgM抗体の定常領域を含む、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, comprising a constant region of an IgG antibody or IgM antibody. う蝕原性生物の宿主となる被験体がヒトであり、キメラモノクローナル抗体は、ヒトIgG抗体またはIgM抗体の定常領域を含む、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, wherein the subject hosting the cariogenic organism is a human and the chimeric monoclonal antibody comprises a constant region of a human IgG antibody or IgM antibody. 組換えキメラモノクローナル抗体としての、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23 as a recombinant chimeric monoclonal antibody. トランスジェニック植物から産生される、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, produced from a transgenic plant. う蝕原性生物の宿主となる被験体が哺乳動物である、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, wherein the subject hosting the cariogenic organism is a mammal. う蝕原性生物の宿主となる被験体が、ヒト、イヌ、またはネコである、請求項２３のキメラモノクローナル抗体。24. The chimeric monoclonal antibody of claim 23, wherein the subject hosting the cariogenic organism is a human, dog or cat.
JP2002520852A 2000-08-24 2000-08-24 Immunological methods of caries prevention Pending JP2004506695A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/023277 WO2002015931A1 (en) 2000-08-24 2000-08-24 Immunologic method for the prevention of dental caries

Publications (2)

Publication Number Publication Date
JP2004506695A JP2004506695A (en) 2004-03-04
JP2004506695A5 true JP2004506695A5 (en) 2005-03-17

Family

ID=21741708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002520852A Pending JP2004506695A (en) 2000-08-24 2000-08-24 Immunological methods of caries prevention

Country Status (4)

Country Link
EP (1) EP1313506A1 (en)
JP (1) JP2004506695A (en)
AU (1) AU2000270698A1 (en)
WO (1) WO2002015931A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143234A1 (en) * 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
US20020068066A1 (en) * 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
US7875598B2 (en) 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
CA2661634C (en) 2006-09-06 2017-03-28 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028937A (en) * 1983-07-25 1985-02-14 Kitasato Inst:The Noncariogenic antibody and composition
JPS6038329A (en) * 1983-08-11 1985-02-27 Lion Corp Preventive for dental caries
US5352446A (en) * 1986-03-25 1994-10-04 Council Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas's Hospitals Method of treating dental caries with monoclonal antibodies against the antigen I and antigen I/II of streptococcus mutans
JP2641228B2 (en) * 1988-01-22 1997-08-13 鐘紡株式会社 Antibody, caries preventive agent containing the same as an active ingredient, and methods for producing the same
JPH02177899A (en) * 1988-12-28 1990-07-10 Nagase Sangyo Kk Igd monoclonal antibody specifically reactive with streptococcus mutans
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH05227916A (en) * 1992-01-11 1993-09-07 Kanebo Ltd Dental caries preventing food
JPH06122633A (en) * 1992-10-09 1994-05-06 Lion Corp Antibody having immunoactivity on streptococcus mutans and dental caries preventive
EP0807173B1 (en) * 1994-12-30 2007-08-08 Planet Biotechnology, Inc. Methods for producing immunoglobulins containing protection proteins in plants and their use
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
EP1105425A1 (en) * 1998-08-21 2001-06-13 The Regents of the University of California Monoclonal antibodies specific for streptococcus mutans, and uses thereof

Similar Documents

Publication Publication Date Title
JP2919071B2 (en) Vaccines against cancer and infectious diseases
JP4153560B2 (en) Treatment of allergic asthma
CA2380783A1 (en) Human monoclonal antibodies to prostate specific membrane antigen
HUP0402653A2 (en) Human antibodies specific for interleukin 15 (il-15)
MX9709778A (en) High affinity human monoclonal antibodies specific for rsv f-protein.
EA200301098A1 (en) ASSOCIATED WITH GANGLIOSIDES RECOMBINANT ANTIBODIES AND THEIR APPLICATION IN DIAGNOSTICS AND TREATMENT OF TUMORS
DE69536072D1 (en) CDR-exchanged type III anti-CEA humanized mouse monoclonal antibodies
JP3392860B2 (en) Anti-idiotype antibodies that induce an immune response to glycosphingolipids and uses thereof
JPH07194390A (en) Immortal lymphocyte for producing anti-idiotype antibody
CA2264810A1 (en) Method of producing active immunity with vaccine conjugate
RU2253655C2 (en) Antiidiotypical antibody for antibodies inhibiting immunoglobulin bonding to its high affinity receptor
JP2004536824A5 (en)
CA2525657C (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats o6 of pseudomonas aeruginosa
DE69737323D1 (en) ADHESIN FROM HELIOBACTER PYLORI BINDING TO BLOOD GROUPSANT
US20120114657A1 (en) Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
JP2004506695A5 (en)
Lai et al. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes
JP2003521219A5 (en)
FR2618680B1 (en) TOXOPLASMA GONDII SPECIFIC EXCRETION-SECRETION ANTIGENS, THEIR EXPRESSION PRODUCTS, THE PROCESS FOR OBTAINING SAME AND THEIR DIAGNOSTIC AND PROPHYLACTIC APPLICATIONS
US6124132A (en) Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus
AT503297B1 (en) Use of antibody or its derivative for preparation of medicament for passive immunization of individual for preventing and/or treating allergic reactions in individual caused by exposure to birch pollen allergen
JP2004523538A5 (en)
JP2006504619A5 (en)
KR890016165A (en) Monoclonal Antibodies to Pseudomonas aeruginosa, Methods for Making and Uses thereof
Jean-François et al. Protection against Streptococcus equi infection by monoclonal antibodies against an M-like protein